GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Cash Receipts from Securities Related Activities

Biosergen AB (FRA:8N1) Cash Receipts from Securities Related Activities


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Biosergen AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.